araag2/HINT huggingface dataset:
Clinical trial NCT01451723 (phase 2, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: polyphenon e
SMILES: OC1=CC(O)=C2C[C@@H](OC(=O)C3=CC(O)=C(O)C(O)=C3)[C@H](OC2=C1)C1=CC(O)=C(O)C(O)=C1
Reason stopped: 
    unusual high frequency of elevated liver function tests.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MS by McDonald criteria

          -  Relapsing-remitting MS or secondary progressive MS

          -  Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six
             months

          -  EDSS Score less than or equal to 7.0

          -  Ages 18-60.

          -  Participants must have normal organ and marrow function as defined below:

               1. Leukocytes ≥3,000/µL

               2. Absolute neutrophil count ≥1,500/µL

               3. Platelets ≥100,000/µL

               4. Total bilirubin ≤local upper limit of normal

               5. AST (SGOT) ≤local upper limit of normal

               6. ALT (SGPT) ≤local upper limit of normal

               7. Creatinine ≤local upper limit of normal

        Exclusion Criteria:

          -  MS relapse within the 30 days prior to enrollment

          -  A primary progressive form of MS.

          -  Previous treatment prior to study entry as follows: complete radiation ablation of the
             bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone,
             cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies
             except the DMT's included in the inclusion criteria and methylprednisone for relapses
             within prior nine months.

          -  History of renal or liver disease.

          -  Consumption of green tea or supplements containing green tea or tea extract within 30
             days prior to enrollment.

          -  Participants may not participate in any other clinical trial involving investigational
             agents during the study, or within six months prior to enrolling in the study.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Polyphenon E, tea, or any of the inactive ingredients present in the
             active or placebo capsules, including gelatin.

          -  History of allergic reactions to gadolinium or any other condition contraindicated for
             MRI.

          -  Uncontrolled, clinically-relevant active illness (aside from MS) including, but not
             limited to, ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements.

          -  Any condition which would make the subject, in the opinion of the investigator,
             unsuitable for the study

          -  Inability to complete the baseline MRI scan

          -  Pregnant women

          -  Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease,
             gastritis, diverticulitis, colitis, hemorrhoids)
Clinical trial NCT00098683 (phase 2, status: completed)
Conditions: myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms
ICD codes: D46.9, D46.C, D46.Z, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: amifostine trihydrate
SMILES: NCCCNCCSP(O)(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of myelodysplastic syndromes (MDS)

               -  One of the following subtypes:

                    -  Refractory anemia (RA)

                    -  RA with ringed sideroblasts

                    -  RA with excess blasts

                    -  Refractory cytopenia with multilineage dysplasia (RCMD)

                    -  RCMD and ringed sideroblasts

                    -  MDS, unclassified

                    -  MDS associated with isolated del 5(q)

          -  De novo disease

               -  No treatment-induced MDS

          -  No juvenile myelomonocytic leukemia

          -  No Down syndrome, Fanconi's anemia, or other inherited forms of hypoplastic bone
             marrow failure

        PATIENT CHARACTERISTICS:

        Age

          -  1 to 21 at original diagnosis

        Performance status

          -  Karnofsky 50-100% (patients > 16 years of age)

          -  Lansky 50-100% (patients 1 to 16 years of age)

        Life expectancy

          -  At least 8 weeks

        Hematopoietic

          -  See Disease Characteristics

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT < 2.5 times ULN

        Renal

          -  Radioisotope glomerular filtration rate ≥ 60 mL/min OR

          -  Creatinine clearance > 60 mL/min (based on Schwartz formula)

          -  Calcium normal

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Serum electrolytes normal

          -  Phosphorus normal

          -  Magnesium normal

          -  Glucose normal

          -  No other concurrent malignancy

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 8 weeks since prior growth factors

          -  No concurrent growth factors

          -  No concurrent hematopoietic stem cell transplantation

          -  No concurrent immunomodulating agents

        Chemotherapy

          -  No prior amifostine

          -  No other concurrent anticancer chemotherapy

        Endocrine therapy

          -  No concurrent daily steroid therapy

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No prior therapy for MDS
Clinical trial NCT00403403 (phase 2, status: completed)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: bevacizumab, chemotherapy, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically documented small cell carcinoma of the bronchus,
             classified as extensive-stage disease

          -  Measurable disease or lesions

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

        Exclusion Criteria:

          -  Life expectancy of < 12 weeks

          -  Current, recent, or planned participation in another experimental drug study

          -  Ongoing or active infection

          -  Active malignancy other than SCLC or superficial basal/squamous cell carcinoma within
             the previous 5 years

          -  Prior systemic therapy, radiation therapy, or surgery for SCLC

          -  Inadequate bone marrow function, renal function, or hepatic function

          -  Serum sodium of < 120 mg/dL

          -  Inadequately controlled hypertension

          -  History of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association Class II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina within 6 months prior to study
             enrollment

          -  History of stroke or transient ischemic attack within 6 months prior to study
             enrollment

          -  Known central nervous system disease, except for brain metastases treated with
             whole-brain radiotherapy

          -  Significant vascular disease or recent peripheral arterial thrombosis within 6 months
             prior to study enrollment

          -  History of hemoptysis within 4 weeks prior to study enrollment

          -  Evidence of bleeding diathesis or coagulopathy in the absence of therapeutic
             anticoagulation

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study enrollment or anticipation of a need for a major surgical procedure
             during the course of the study

          -  Core biopsy or other minor surgical procedure, including placement of a vascular
             access device, within 7 days prior to Day 1

          -  History of abdominal fistula or gastrointestinal perforation within 6 months prior to
             study enrollment

          -  Serious, non-healing wound, active ulcer, or untreated bone fracture

          -  Known hypersensitivity to any component of bevacizumab

          -  Pregnant (positive pregnancy test) or lactating
Clinical trial NCT00720447 (phase 2, status: unknown status)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: carmustine, cytarabine, etoposide, melphalan
SMILES: ClCCNC(=O)N(CCCl)N=O, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of mantle cell lymphoma

          -  No relapsed or progressive disease

          -  Achieved at least a partial remission following induction chemotherapy

          -  HLA-matched donor available

          -  Blood samples from both patient and donor available for chimerism studies

          -  No central nervous system involvement

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 2-4

          -  Considered fit for transplant by treating physician

          -  Serum bilirubin ≤ 1.5 times upper limit of normal

          -  Alkaline phosphatase ≤ 2 times normal

          -  Creatinine clearance ≥ 50 mL/min

          -  Ejection fraction > 50% (no inadequate cardiac function)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  No symptomatic respiratory compromise

          -  No serious concurrent disease which would preclude allograft

          -  No known serological positivity for hepatitis B, hepatitis C, or HIV

          -  No history of a psychological illness or condition that would affect compliance

          -  No previous malignancy within the past 5 years except nonmelanoma skin tumors or stage
             0 (in situ) cervical carcinoma

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
Clinical trial NCT00371254 (phase 2, status: completed)
Conditions: breast cancer, metastasis
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: dasatinib, dasatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  females, 18 or older

          -  recurrent or progressive locally advanced, or 'triple negative' metastatic breast
             cancer

          -  paraffin-embedded tissue block must be available

          -  measurable disease

          -  prior chemotherapy with an anthracycline, a taxane, or both (neoadjuvant, adjuvant, or
             metastatic setting)

          -  0, 1 or 2 chemotherapies in the metastatic setting

          -  adequate organ function

        Exclusion Criteria:

          -  Metastatic disease confined to bone only

          -  Symptomatic CNS metastasis

          -  Concurrent medical condition which may increase the risk of toxicity

          -  Unable to take oral medication
Clinical trial NCT00630994 (phase 2, status: terminated)
Conditions: chronic myeloproliferative disorders, secondary myelofibrosis
ICD codes: D47.1, D75.81, C94.41, C94.42, C94.40
Drugs: dacogen
SMILES: NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
Reason stopped: 
    stopped due to slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histological confirmation of primary myelofibrosis or post essential thrombocythemic
             or polycythemic vera myelofibrosis

               -  Reticulin fibrosis ≥ grade 1

          -  Evaluable and symptomatic disease worthy of treatment, characterized by ≥ 1 of the
             following:

               -  Anemia, defined as hemoglobin < 11 g/dL or erythrocyte transfusion dependence

               -  Palpable and symptomatic splenomegaly (palpable and symptomatic hepatomegaly is
                  acceptable if previously splenectomized)

               -  Severe, disease-related constitutional symptoms, including ≥ 1 of the following:

                    -  Severe night sweats

                    -  Fevers

                    -  Weight loss

                    -  Bone pain

          -  Absence of t(9;22) by fluorescent in situ hybridization (FISH) or standard
             cytogenetics OR prior demonstration of a lack of this translocation

        PATIENT CHARACTERISTICS:

          -  Eastern Co-operative Oncology Group (ECOG) performance status 0-3

          -  Absolute neutrophil count (ANC) ≥ 1,000/mm³

          -  Platelet count ≥ 50,000/mm³

          -  Creatinine ≤ 2.0 mg/dL

          -  Direct or total bilirubin ≤ 2.0 mg/dL

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times upper
             limit of normal (ULN) (≤ 5 times ULN if elevation is attributed to hepatic
             extramedullary hematopoiesis)

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Not incarcerated in a municipality, county, state, or federal prison

          -  No serious medical condition or psychiatric illness that would preclude signing the
             informed consent

          -  No condition that, in the opinion of the treating physician, places the patient at
             unacceptable risk for study participation or confounds the ability to interpret study
             data

          -  Able to adhere to the study visit schedule and other study requirements

        PRIOR CONCURRENT THERAPY:

          -  No other concurrent chemotherapy (e.g., hydroxyurea, thalidomide, interferon alpha,
             anagrelide, or other myelosuppressive agent) or experimental therapy
Clinical trial NCT01596504 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: lixisenatide (ave0010), liraglutide, insulin glargine, metformin
SMILES: [V].[H][C@](C)(O)[C@]([H])(N=C(O)CN=C(O)[C@]([H])(CCC(O)=O)N=C(O)CN=C(O)[C@@]([H])(N)CC1=CN=CN1)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCC(O)=N)C(O)=N[C@@]([H])(CCSC)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(C)C(O)=N[C@@]([H])(C(C)C)C(O)=N[C@@]([H])(CCCNC(N)=N)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@]([H])(C(O)=N[C@@]([H])(CCC(O)=O)C(O)=N[C@@]([H])(CC1=CNC2=CC=CC=C12)C(O)=N[C@@]([H])(CC(C)C)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CC(O)=N)C(O)=NCC(O)=NCC(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CO)C(O)=NCC(O)=N[C@@]([H])(C)C(=O)N1CCC[C@@]1([H])C(=O)N1CCC[C@@]1([H])C(O)=N[C@@]([H])(CO)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N[C@@]([H])(CCCCN)C(O)=N)[C@@]([H])(C)CC)[C@@]([H])(C)O, CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion criteria :

          -  Participants with T2DM diagnosed at least 1 year before the screening visit.

          -  Treatment with neutral protamine hagedorn (NPH) or insulin glargine for at least 3
             months and at a stable dose (±20%) of at least 10 IU/day (for at least 2 months prior
             to screening) alone or combined with a stable dose of metformin with or without
             dipeptidyl peptidase 4 (DPP-4) inhibitor or sulfonylurea.

          -  Glycosylated hemoglobin (HbA1c) ≥6.5 and ≤9.5%.

          -  Body mass index (BMI) between 20 and 40 kg/m^2.

        Exclusion criteria:

          -  Pregnant women or breastfeeding women.

          -  Clinically relevant history of gastrointestinal disease associated with prolonged
             nausea and vomiting, including, but not limited to, gastroparesis and gastroesophageal
             reflux disease requiring medical treatment within 6 months prior to the time of
             screening.

          -  Any previous treatment with lixisenatide or participation in a previous study with
             lixisenatide (AVE0010), and any previous treatment with liraglutide stopped for safety
             concern or lack of efficacy.

          -  Allergic reaction to any glucagon-like peptide-1 (GLP-1) agonist in the past (eg,
             exenatide) or to metacresol.

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
             stomach/gastric surgery, inflammatory bowel disease.

          -  Personal or family history of medullary thyroid cancer (MTC) or a genetic condition
             that predisposes to MTC.

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT00605553 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: placebo, tozadenant
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Parkinson's disease

          -  Hoen and Yahr stage 1-3

          -  On stable dose of anti-parkinsons treatment for 30 days prior to screening

          -  Age 40 to 75 years

          -  Sign an IRB approved informed consent

          -  Men and women agree to use adequate birth control

          -  ECG measurements are within normal limits

          -  Able to understand study requirements

        Exclusion Criteria:

          -  Secondary Parkinson's (drug induced or post stroke)

          -  Received treatment with other investigational drug 30 days prior to study entry

          -  Using disallowed medications

          -  Significant neurological illness other than Parkinson's

          -  IQ less than 70 on IQ test

          -  MMSE score < or = 23

          -  History of psychosis or on anti-psychotic medication

          -  Current serious medical illness

          -  History of substance abuse

          -  History of head injury with loss of consciousness

          -  History of brain surgery

          -  Contraindications to MRI like claustrophobia, metal implants or other implantable
             devices

          -  Abnormal liver function tests and/or hepatitis or cholangitis

          -  Gilberts disease

          -  Pregnant or nursing

          -  Known hypersensitivity to SYN115
Clinical trial NCT00017173 (phase 2, status: terminated)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    terminated for poor accrual.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed high-risk/limited stage III or IV squamous cell carcinoma of
             the oral cavity, oropharynx, hypopharynx, and larynx

               -  Newly diagnosed

               -  Previously untreated

               -  Considered surgically resectable

               -  Evidence of regional lymph node metastases (N1-N3)

          -  No distant metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Not specified

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)

          -  SGOT or SGPT no greater than 3 times ULN

          -  Hepatitis B surface antigen negative

          -  Hepatitis C antibody negative

        Renal:

          -  Creatinine no greater than 2 times ULN

          -  Creatinine clearance at least 60 mL/min

        Other:

          -  Magnesium normal (magnesium supplement allowed)

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer in complete remission

          -  HIV negative

          -  Not pregnant or nursing

          -  Patients must use effective barrier contraception and prevent bodily fluid
             transmission during and for 28 days after Ad5CMV-p53 gene administration

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Not specified

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No concurrent intensity-modulated radiotherapy

        Surgery:

          -  Not specified
Clinical trial NCT00429091 (phase 2, status: completed)
Conditions: attention-deficit/hyperactivity disorder, adhd
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: abt-894, atomoxetine, placebo
SMILES: ClC1=C(Cl)N=CC(=C1)N1C[C@@H]2CN[C@@H]2C1, CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Meet criteria for attention-deficit/hyperactivity disorder

          -  Have voluntarily signed an informed form

          -  Are between 18 and 60 years of age

          -  Will use contraceptive methods during the study

          -  Women must not be pregnant or breast-feeding

          -  Must be in generally good health

          -  Are fluent in English

        Exclusion Criteria:

          -  They have a current or past diagnosis of schizoaffective disorder, schizophrenia,
             obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic
             disorder or mental retardation

          -  They have a current diagnosis of major depressive episode, generalized anxiety
             disorder (GAD), or post-traumatic stress disorder (PTSD) or has a clinically
             significant sleep disorder requiring treatment

          -  They require ongoing treatment or expected treatment with any psychotropic medication,
             including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood
             stabilizers, nicotine replacement therapies or varenicline

          -  They require ongoing treatment or expected treatment with Coumadin

          -  They failed to respond to two or more adequate trials of FDA-approved ADHD medication

          -  They have taken atomoxetine during the last 3 months

          -  They have violent, homicidal or suicidal ideation

          -  They have a significant history of medical diagnoses, seizure disorder, Tourette's
             syndrome, traumatic brain injury, or a central nervous system (CNS) disease, excluding
             ADHD

          -  They have a urine drug screen that is positive for alcohol or drugs of abuse

          -  They have a history of substance or alcohol disorder during the last 3 months